Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Corporate Update (November 2021)
20 slides from Nykode Therapeutics Asa's corporate update, Nov 23, 2021
Slide 1: License and collaboration agreement with Regeneron
License and collaboration agreement with Regeneron Vaccibody becomes Nykode Therapeutics November 23, 2021
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Agenda
Agenda License and collaboration agreement with Regeneron Vaccibody becomes Nykode Therapeutics Nykode Therapeutics | Webcast | Non-confidential 3
Slide 4: Nykode enters into multi-target license and collaboration agreement with Regeneron
Nykode Therapeutics enters into multi- target license and collaboration agreement with Regeneron to develop innovative vaccines against cancer and infectious diseases Nykode Therapeutics | Webcast | Non-confidential 4
Slide 5: Vaccibody becomes Nykode Therapeutics
Vaccibody becomes Nykode Therapeutics Nykode Therapeutics | Webcast | Non-confidential 5
Slide 6: Nykode Therapeutics – Unique vaccine and novel therapeutic platform
Nykode Therapeutics – Unique vaccine and novel therapeutic platform Clinical stage immunotherapy company Leading vaccine technology platform targeting antigens to antigen presenting cells Well tolerated, easily manufactured and induce robust CD8 and CD4 T cell responses Platform can fuel mul
Slide 7: 01 Regeneron collaboration
01 Regeneron collaboration Multitarget, exclusive license and collaboration agreement 7
Slide 8: Regeneron – Nykode Therapeutics collaboration overview
Regeneron – Nykode Therapeutics collaboration overview DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF 5 NOVEL VACCINE PROGRAMS AGAINST CANCER AND INFECTIOUS DISEASES Vaccine generation Antigen identification Vaccine characterization Preclinical development Product supply through phase 1
Slide 9: Regeneron – Nykode Therapeutics deal terms overview
Regeneron – Nykode Therapeutics deal terms overview 3 oncology and 2 novel infectious disease programs, each may include several vaccine candidates Regeneron to cover all research, development and commercialization costs Upfront of USD 30 million and USD 20 million equity investment at 20% pre
Slide 10: Pipeline
Pipeline Broad oncology coverage and strong partnerships. Leveraging platform within infectious diseases Upcoming Program Indication Discovery/Preclinical Phase 1 Phase 2 Phase 3 Partnerships Milestones Oncology Off the shelf 2H21: Trial Fully VB10.16 HPV16+ cervical cancer3 Enrolled 1H22: Interim D
Slide 11: Regeneron is a partner of choice for Nykode Therapeutics
Regeneron is a partner of choice for Nykode Therapeutics REGENERON OVERVIEW 10,000+ employees Scientifically led and focused on innovative Deep scientific expertise and drug development successful track record Brings unique insights on antigen selection for the collaboration programs Proven
Slide 12: Perfect fit with Nykode Therapeutics growth strategy
Perfect fit with Nykode Therapeutics growth strategy Validates our unique therapeutic vaccine platform Expands and fast tracks our pipeline into novel and innovative areas across oncology and infectious diseases Fully complementary to current and future pipeline Cash flow allows us to accele
Slide 13: 02 Vaccibody becomes Nykode Therapeutics
02 Vaccibody becomes Nykode Therapeutics 13
Slide 14: Transforming the Company from vaccines to a broader platform
Transforming the Company from vaccines to a broader platform Three major deals proving our leading vaccine platform Generated several hundred novel constructs and built know-how in coding new medicines with unique properties Continued focus on innovation - improve and expand our modular elemen
Slide 15: Building further on our core strength
Building further on our core strength COMBINING MODULAR ELEMENTS TO GENERATE SUPERIOR MEDICINES Breaking down the boundaries of conventional drug design Combining genes to generate novel drugs with unique properties Nykode Therapeutics | Webcast | Non-confidential 15
Slide 16: New name captures ambition of platform and Norwegian heritage
New name captures ambition of platform and Norwegian heritage Encapsulates vision of finding new ways of coding Coding novel medicine medicines Draws on our heritage by using the Norwegian words for the words new “ny” and code “kode” Nykode Therapeutics | Webcast | Non-confidential 16
Slide 17: Nykode's modular platform enables generation of multiple specific and innovative products
Nykode’s modular platform enables generation of multiple specific and innovative products APC-specific Ag delivery and Expanded use of modularity stimulation Building additional Novel Infectious disease Cancer vaccines combinations and vaccines modules structures Vaccines against Novel therapeutics
Slide 18: Signifying a new phase of growth and development
Signifying a new phase of growth and development Exploiting future potential building on our core competences Significantly expanding our pipeline through internal and selected partnered programs With a common basis of generating novel Building the organization with strong focus on continuous
Slide 19: Strong financial foundation for achieving our vision
Strong financial foundation for achieving our vision Financially well positioned to grow and execute the Company’s strategy over the next years Total available liquidity of USD 189 million on September 30, 2021 − Cash and cash equivalents of USD 172.6 million − Liquid money market funds of USD 1
Slide 20: Thank you
Contact Michael Engsig CEO IR@vaccibody.com THANK YOU Nykode Therapeutics | Webcast | Non-confidential
Nykode Therapeutics — Corporate Update (November 2021) on 6ix